Incyte Claims Sun Pharma's Alopecia Drug Launch Violates IP
Incyte has fought back against the Indian pharmaceutical company Sun Pharma's bid to nix three patents protecting a blockbuster drug treating autoimmune conditions, arguing that once it launches in 2026, Sun...To view the full article, register now.
Already a subscriber? Click here to view full article